Drug discovery data automation company raises funding

ReSync Bio, a scientific software provider accelerating preclinical research and development, announced its official launch and a funding round from Caffeinated Capital, Atria Ventures and leading angel investors including Ramsey Homsany, co-founder of Octant Bio. The company will use the funds to make key hires and commercialize its platform, which is now available for use by companies and scientists.

Preclinical drug development is currently being held back by numerous bottlenecks. And disparate software tools make it difficult to coordinate data across different computing models, internal labs, and contract research organizations (CROs). The disorganized and siled data makes it difficult to adopt modern AI tools. This forces pharmaceutical and biotechnology companies to continually reinvent data technology with customized solutions that rob their science of time and resources.

ReSync was inspired by Trivedi's time as an early engineer at PostEra, where he saw firsthand the need for more standard tools for AI-driven drug discovery. And ReSync's platform is designed to help companies organize and train their data, models and experimental workflows more efficiently.

ReSync's platform also automates coordination between drug discovery teams and their labs – whether they are internal or external CROs. And the software includes tightly controlled permissions, allowing companies to control data access and promote collaboration while protecting intellectual property.

MOST IMPORTANT QUOTES:

“Our mission is to accelerate drug discovery programs across the industry. AI advances in generative drug discovery have transformed throughput on the digital side, but major challenges remain in translating these advances to the experimental side of life sciences, where it takes far too long to go from idea to test data. ReSync is a bridge that synergistically connects the digital and experimental worlds to bring therapeutics to the clinic faster.”

“ReSync’s goal is to make therapeutics companies more efficient so they can make decisions faster and ultimately get therapies to the clinic – and to patients – quickly.”

-ReSync founder and CEO Mihir Trivedi

“The reality in the lab today is that AI drug discovery programs are hampered by uncoordinated experiments and unstructured data. ReSync is a universal tool that enables any life sciences company to eliminate preclinical bottlenecks and use their data more intelligently. ReSync is the essential life sciences automation layer that enables AI bioacceleration.”

-Chris Head of Atria Ventures

“Companies like Microsoft and NVIDIA are investing billions in AI-powered drug discovery platforms and services, but there is still a huge unmet need for better data infrastructure to realize the potential of these technologies. We believe ReSync can become a cornerstone of AI drug discovery, enabling hundreds of other companies to bring life-saving therapeutics to market.”

-Varun Gupta of Caffeinated Capital